Received Aug 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | X019102 | OT / LL |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y004554 | OT / RL |
No additional AEs/PQC reported; vaccines administered after temperature excursions.; This spontaneous report was received from an other health professional and refers to unknown number of patients of unknown age and gender. The patients' medical history was not reported. The patients' concurrent conditions were not reported. Concomitant therapies were not reported. On unknown dates, the patients started therapy with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (lot #X019102, expiration date: 16-Jul-2025) for the treatment of Prophylaxis. On unknown dates, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Y013066, expiration date: 29-Jul-2026) for the treatment of Prophylaxis. On unknown dates, the patients started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Y004554, expiration date: 20-Feb-2026) for the treatment of Prophylaxis. On unknown dates, the patients started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y017514, expiration date: 19-Apr-2026) for the treatment of Prophylaxis. On unknown dates, the patients started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y019171, expiration date: 18-May-2026) for the treatment of Prophylaxis. On unknown dates, the patients started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y013582, expiration date: 03-Feb-2026) for the treatment of Prophylaxis. These vaccines were reconstituted with sterile diluent (MERCK STERILE DILUENT) (expiration date, and lot # were not reported). On an unknown date, the patient experienced vaccines administered after temperature excursions. There was also previous temperature excursion. No other information provided. No additional AEs/PQC reported. At the reporting time, the outcome of the events was unknown. The action taken with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live. Varicella Virus Vaccine Live (Oka-Merck). Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live and sterile diluent was reported as not applicable. Follow up was received from a nurse on 31-JUL-2025, regarding a 1-year-old male patient. On 29-MAR-2025, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) 0.5 ml injection (lot #X019102, expiration date: 16-Jul-2025) Intramuscularly via Left Thigh and Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), 0.5 ml injection (lot #Y004554, expiration date: 20-Feb-2026) Subcutaneously via Right Thigh for Prophylaxis with sterile diluent (MERCK STERILE DILUENT) (Product storage error). Temperature excursion occurred a result of a reading from a Digital Data Logger and both vaccines were given prior to known excursion. The patient did not receive Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD). This is an invalid report due to provided identifiers (previously invalid case). The is one of several reports from the same reporter.
Sterile Diluent